A study using human breast cancer cell lines and mouse tumor xenografts has shown that activating mutations of PIK3CA and/or decreased expression of PTEN could be responsible of resistance to lapatinib and that this resistance is reversible by double blockade of PI3KCA and mTOR [45]. The gene discussed is PIK3CA; the disease is breast carcinoma.